Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Afatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 10/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 2/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 2/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 2/20 | 1.00 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 1.00 |
| ▸ | EPHA6 | Q9UF33 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afatinib SCHEMBL28567422 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL185621 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL232772 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL29733662 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL231072 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL185786 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL2865630 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL2269415 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL231073 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL2865634 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355330-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | Genentech, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| WO-2022265950-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| CN-115298198-A | Novel compounds and compositions for targeted therapy of kidney-related cancers | 上海盟科药业股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| WO-2026102277-A1 | COMBINATION THERAPIES COMPRISING IKZF2 DEGRADER COMPOUNDS | Plexium, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4730355-A1 | TYPING SYSTEM AND METHOD FOR HR-POSITIVE/HER2-NEGATIVE BREAST CANCER | Lumitype Medical (Huzhou) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-20260048084-A1 | METHODS OF ADMINISTERING NATURAL KILLER CELLS COMPRISING AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) CHIMERIC ANTIGEN RECEPTOR (CAR) | ARTIVA BIOTHERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2025238176-A1 | COMBINATIONS OF EGFR/ERB AND BET INHIBITORS FOR GASTRIC CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4568674-A1 | COMBINATION OF ANTICANCER AGENTS COMPRISING A BIFUNCTIONAL COMPOUND WITH G12D MUTANT KRAS INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2025-06-18 | — | — | EP | disclosed |
| EP-4562010-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | Novartis AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| EP-4048273-A1 | NOVEL DRUG COMBINATIONS FOR TREATMENT OF A CARCINOMA | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-08-31 | — | — | EP | disclosed |
| EP-4048270-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITORS | Lupin Limited (IN) | 2022-08-31 | — | — | EP | disclosed |
| WO-2022157629-A1 | PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER | LUPIN LIMITED (IN) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022133057-A1 | TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY | ARTIVA BIOTHERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022133056-A1 | EXPANDED AND STIMULATED NATURAL KILLER CELLS | ARTIVA BIOTHERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-4007592-A1 | ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER | LanthioPep B.V. (NL) | 2022-06-08 | — | — | EP | disclosed |
| CN-112898277-B | Preparation method of afatinib intermediate | 扬子江药业集团有限公司 | 2022-04-22 | — | — | CN | disclosed |
| WO-2022043558-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043557-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048084-A1 | METHODS OF ADMINISTERING NATURAL KILLER CELLS COMPRISING AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) CHIMERIC ANTIGEN RECEPTOR (CAR) | PBK, HAVCR2, FCGR2A | EGFR 9/4885ERBB2 11/4885ERBB4 45/4885 |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | EGFR 2414/4885ERBB2 1580/4885ERBB4 1681/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | EGFR 2095/4885ERBB2 1560/4885ERBB4 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.